These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 2163227)

  • 1. [How to standardize low molecular weight heparins].
    Doutremepuich C; Puyal C; Lalanne MC; Doutremepuich F; De Sèze O
    Ann Biol Clin (Paris); 1990; 48(4):221-5. PubMed ID: 2163227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low molecular weight heparins: antithrombotic and haemorrhagic effects and standardization.
    Barrowcliffe TW; Thomas DP
    Acta Chir Scand Suppl; 1988; 543():57-64. PubMed ID: 2847459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein lipase, hepatic lipase and plasma lipolytic activity. Effects of heparin and a low molecular weight heparin fragment (Fragmin).
    Persson E
    Acta Med Scand Suppl; 1988; 724():1-56. PubMed ID: 2843005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
    Peyrou V; Béguin S; Boneu B; Hemker HC
    Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of low molecular weight heparin ex vivo activities in clinical laboratories using various anti-Xa assays: interlaboratory variability and requirement for an agreed low molecular weight heparin standard.
    Sié P; Aillaud MF; de Prost D; Droullé C; Forestier F; Guedj P; Juhan-Vague I; Polack B; Potron G; Roncato M
    Thromb Haemost; 1987 Oct; 58(3):879-83. PubMed ID: 2829376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination.
    Grimaudo V; Omri A; Kruithof EK; Hauert J; Bachmann F
    Thromb Haemost; 1988 Jun; 59(3):388-91. PubMed ID: 2847348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anticoagulant activity of low-molecular-weight heparins obtained using a hydrolase complex].
    Drozd NN; Tolstenkov AS; Bannikova GE; Miftakhova NT; Lapikova ES; Makarov VA; Varlamov VP
    Eksp Klin Farmakol; 2007; 70(6):19-24. PubMed ID: 18318190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new chronometric assay to determine plasma antifactor Xa activity which is insensitive to the antithrombin activity of low molecular weight heparins.
    Dignac M; Gabaig AM; Cambus JP; Boneu B
    Nouv Rev Fr Hematol (1978); 1994; 35(6):545-9. PubMed ID: 8152901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [From heparin to heparins: toward new therapeutic perspectives?].
    Molho P; Tobelem G
    Biomed Pharmacother; 1987; 41(4):171-5. PubMed ID: 3620582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of low-molecular-weight heparin reversal by platelet factor 4.
    Fiore MM; Mackie IM
    Thromb Res; 2009 May; 124(1):149-55. PubMed ID: 19195682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low molecular weight heparins--state-of-the-art and unsolved issues.
    Breddin HK
    Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S17-9. PubMed ID: 8180324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers.
    Eriksson BI; Söderberg K; Widlund L; Wandeli B; Tengborn L; Risberg B
    Thromb Haemost; 1995 Mar; 73(3):398-401. PubMed ID: 7667822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production and chemical processing of low molecular weight heparins.
    Linhardt RJ; Gunay NS
    Semin Thromb Hemost; 1999; 25 Suppl 3():5-16. PubMed ID: 10549711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are the available low-molecular-weight heparin preparations the same?
    Fareed J; Jeske W; Hoppensteadt D; Clarizio R; Walenga JM
    Semin Thromb Hemost; 1996; 22 Suppl 1():77-91. PubMed ID: 8807734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
    Pindur G; Heiden M; Köhler M
    Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low molecular weight heparin therapy: is monitoring needed?
    Boneu B
    Thromb Haemost; 1994 Sep; 72(3):330-4. PubMed ID: 7855780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-course of anti-Xa effects of calcium heparin and low-molecular-weight heparin given s.c.: insights for thrombosis prevention.
    Romeo G; Salanitri G; Catania G
    Drugs Exp Clin Res; 1988; 14(6):423-7. PubMed ID: 2850903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Low molecular weight heparins].
    Doutremepuich C; Lalanne MC; Guyot M; Doutremepuich F; Fernandez G; De Seze O; Deharo E; Vairel EG; Quilichini R
    Ann Pharm Fr; 1989; 47(3):109-16. PubMed ID: 2561387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
    Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective.
    Favaloro EJ; Bonar R; Aboud M; Low J; Sioufi J; Wheeler M; Lloyd J; Street A; Marsden K;
    Lab Hematol; 2005; 11(3):157-62. PubMed ID: 16174600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.